AU2353701A - Transepithelial delivery of glp-1 derivatives - Google Patents
Transepithelial delivery of glp-1 derivativesInfo
- Publication number
- AU2353701A AU2353701A AU23537/01A AU2353701A AU2353701A AU 2353701 A AU2353701 A AU 2353701A AU 23537/01 A AU23537/01 A AU 23537/01A AU 2353701 A AU2353701 A AU 2353701A AU 2353701 A AU2353701 A AU 2353701A
- Authority
- AU
- Australia
- Prior art keywords
- glp
- derivatives
- transepithelial delivery
- transepithelial
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200000030 | 2000-01-11 | ||
| DKPA200000030 | 2000-01-11 | ||
| PCT/DK2001/000015 WO2001051071A2 (en) | 2000-01-11 | 2001-01-11 | Transepithelial delivery of glp-1 derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2353701A true AU2353701A (en) | 2001-07-24 |
Family
ID=8158907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU23537/01A Abandoned AU2353701A (en) | 2000-01-11 | 2001-01-11 | Transepithelial delivery of glp-1 derivatives |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1250126A2 (en) |
| JP (1) | JP2003519664A (en) |
| AU (1) | AU2353701A (en) |
| WO (1) | WO2001051071A2 (en) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| US20030119734A1 (en) | 2001-06-28 | 2003-06-26 | Flink James M. | Stable formulation of modified GLP-1 |
| AU2003220125B2 (en) | 2002-03-20 | 2006-06-15 | Mannkind Corporation | Inhalation apparatus |
| JP2007524592A (en) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー／エス | Stabilized pharmaceutical peptide composition |
| US8921311B2 (en) | 2003-08-01 | 2014-12-30 | Mannkind Corporation | Method for treating hyperglycemia |
| JP2007537981A (en) * | 2003-09-19 | 2007-12-27 | ノボ ノルディスク アクティーゼルスカブ | Novel plasma protein affinity tag |
| WO2005027978A2 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| ATE525083T1 (en) * | 2003-11-13 | 2011-10-15 | Novo Nordisk As | PHARMACEUTICAL COMPOSITION COMPRISING AN INSULINOTROPIC GLP-1(7-37) ANALOG, ASP(B28) INSULIN, AND A SURFACE-ACTIVE COMPOUND |
| US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
| CN1882356B (en) | 2003-11-20 | 2015-02-25 | 诺沃挪第克公司 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| BRPI0417717A (en) | 2003-12-18 | 2007-04-03 | Novo Nordisk As | compound, pharmaceutical composition, and use of a compound |
| DE602005024413D1 (en) | 2004-08-20 | 2010-12-09 | Mannkind Corp | CATALYSIS OF DIKETOPIPERAZINE SYNTHESIS |
| EP2322180B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Diketopiperazine salts for drug delivery |
| US7442682B2 (en) * | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
| RU2413530C9 (en) | 2004-11-12 | 2021-05-18 | Ново Нордиск А/С | Stable preparations of insulin peptides |
| WO2006087354A2 (en) * | 2005-02-16 | 2006-08-24 | Novo Nordisk A/S | Insulinotropic agents conjugated with structurally well defined branched polymers |
| CA2596926A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Extended glp-1 compounds |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CN101184509A (en) * | 2005-05-27 | 2008-05-21 | 阿斯比奥制药株式会社 | Agent for improvement of insulin resistance |
| CN102614131A (en) | 2005-09-14 | 2012-08-01 | 曼金德公司 | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| BRPI0707991B8 (en) | 2006-02-22 | 2021-05-25 | Mannkind Corp | methods of preparing a dry powder medicine with an improved pharmaceutical property, said dry powder and using an effective amount of the dry powder |
| EP2954893A1 (en) * | 2007-10-24 | 2015-12-16 | MannKind Corporation | An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes |
| IL313823A (en) | 2008-06-13 | 2024-08-01 | Mannkind Corp | Dry powder inhaler and drug delivery system |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| AU2009259883B2 (en) | 2008-06-20 | 2015-02-05 | Mannkind Corporation | An interactive apparatus and method for real-time profiling of inhalation efforts |
| BRPI0917000A2 (en) | 2008-08-06 | 2016-02-16 | Novo Nordisk Healthcare Ag | protein conjugates with prolonged in vivo efficacy |
| TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
| PL2349324T3 (en) | 2008-10-17 | 2018-02-28 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| JP5918539B2 (en) | 2009-01-08 | 2016-05-18 | マンカインド コーポレイション | Method for treating hyperglycemia using GLP-1 |
| ES2542202T3 (en) | 2009-01-22 | 2015-08-03 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
| CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| KR20190090092A (en) | 2009-06-12 | 2019-07-31 | 맨카인드 코포레이션 | Diketopiperazine microparticles with defined specific surface areas |
| US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
| EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
| PT3345593T (en) * | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine |
| PT3417871T (en) | 2009-11-13 | 2021-02-15 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1-agonist, an insulin, and methionine |
| RU2012134974A (en) | 2010-01-22 | 2014-02-27 | Ново Нордиск Хелс Кеа Аг | STABILIZED GROWTH HORMONE COMPOUND |
| CN106139158B (en) | 2010-01-22 | 2024-06-21 | 诺沃—诺迪斯克保健股份有限公司 | Growth hormone with prolonged in vivo efficacy |
| KR20130117755A (en) | 2010-06-21 | 2013-10-28 | 맨카인드 코포레이션 | Dry powder drug delivery system and methods |
| SI2611458T1 (en) | 2010-08-30 | 2017-01-31 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| MX353285B (en) | 2011-04-01 | 2018-01-05 | Mannkind Corp | Blister package for pharmaceutical cartridges. |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| BR112014004726A2 (en) | 2011-08-29 | 2017-04-04 | Sanofi Aventis Deutschland | pharmaceutical combination for use in glycemic control in type 2 diabetes patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| BR112014009686A2 (en) | 2011-10-24 | 2018-08-07 | Mannkind Corp | Inhalable analgesic composition, dry powder and method for treating pain |
| ES2629735T3 (en) | 2012-05-08 | 2017-08-14 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| BR112015000529B1 (en) | 2012-07-12 | 2022-01-11 | Mannkind Corporation | DRY POWDER INHALER |
| US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
| TWI641381B (en) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| KR102391750B1 (en) | 2013-03-15 | 2022-04-28 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
| US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
| BR112016000937A8 (en) | 2013-07-18 | 2021-06-22 | Mannkind Corp | dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation |
| CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
| MX2016008978A (en) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives. |
| CN114939156A (en) | 2014-01-09 | 2022-08-26 | 赛诺菲 | Stabilized pharmaceutical formulations of insulin aspart |
| CN105960249B (en) | 2014-01-09 | 2021-03-16 | 赛诺菲 | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| PE20171622A1 (en) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION |
| TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
| TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
| MY198425A (en) | 2017-08-24 | 2023-08-29 | Novo Nordisk As | Glp-1 Compositions and uses Thereof |
| US20230082544A1 (en) | 2020-02-18 | 2023-03-16 | Novo Nordisk A/S | Pharmaceutical formulations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK36492D0 (en) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | PREPARATION |
| DE69916811T2 (en) * | 1998-02-27 | 2005-04-14 | Novo Nordisk A/S | GLP-1 DERIVATIVES HAVING A HELIX CONTENT OVER 25% FOR PARTIALLY MADE STRUCTURED MICRO-SPECIFIC AGGREGATES |
| EP1056775B1 (en) * | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| BR9913284A (en) * | 1998-08-28 | 2001-05-15 | Lilly Co Eli | Methods for administering insulinotropic peptides |
-
2001
- 2001-01-11 AU AU23537/01A patent/AU2353701A/en not_active Abandoned
- 2001-01-11 EP EP01900109A patent/EP1250126A2/en not_active Withdrawn
- 2001-01-11 JP JP2001551494A patent/JP2003519664A/en active Pending
- 2001-01-11 WO PCT/DK2001/000015 patent/WO2001051071A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001051071A3 (en) | 2002-01-24 |
| JP2003519664A (en) | 2003-06-24 |
| WO2001051071A2 (en) | 2001-07-19 |
| EP1250126A2 (en) | 2002-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2353701A (en) | Transepithelial delivery of glp-1 derivatives | |
| AU2001234567A1 (en) | Guaranteed exactly once delivery of messages | |
| AU5259100A (en) | Medicament | |
| AU2002217979A1 (en) | Medicine feeder | |
| AU2001227858A1 (en) | Delivery of cardiac constraint jacket | |
| AU2001269529A1 (en) | Medicine comprising dicyanopyridine derivative | |
| AU2002223028A1 (en) | Inhaler | |
| AU2002218250A1 (en) | Medicament dispenser | |
| AU2001260327A1 (en) | Chair | |
| AU2002221168A1 (en) | Folding chair | |
| AU6887401A (en) | Delivery of remotely-ordered products | |
| AU2002223562A1 (en) | Medicament dispenser | |
| AU2001284444A1 (en) | Preparations for oral administration | |
| AU2001278694A1 (en) | Avermectin derivatives | |
| AU1557901A (en) | Chair | |
| AU2001284763A1 (en) | Preparation of risperidone | |
| AU3918501A (en) | Atomiser | |
| AU2001293911A1 (en) | Medical home-service modular terminal | |
| AU2002222557A1 (en) | Interferon therapeutic effect-potentiating agents | |
| AU2002239279A1 (en) | Oral nanosphere delivery | |
| AU2721900A (en) | Folding chair | |
| AU2001252200A1 (en) | Chair | |
| AU2001272718A1 (en) | Medicaments | |
| AU2001244854A1 (en) | Local drug delivery | |
| AU2002215902A1 (en) | Medicament dispenser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |